Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of DNA vaccines with AddaS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2

16 Jun 2023

Abstract excerpt

Emerging variants of SARS-CoV-2 call for frequent changes in vaccine antigens. Nucleic acid-based vaccination strategies are superior as the coding sequences can be easily altered with little impact on downstream production. mRNA vaccines, including variant-specific boosters, are approved for SARS-CoV-2. Here, we tested the efficacy of DNA vaccines against the SARS-CoV-2 Spike aided by the AddaS03 adjuvant using...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Animal Virus Infections Studies
Share to SARS-CoV-2 and COVID-19 Research
Share to Viral gastroenteritis research and epidemiology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37361876
DOI: 10.1016/j.isci.2023.107120

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of DNA vaccines with AddaS03 as an adjuvant and an mRNA vaccine against SARS-CoV-2PMID 37361876Read ↗

Engineering of the current nucleoside-modified mRNA-LNP vaccines against SARS-CoV-2Semantic proximity Read ↗

Next‐Generation Vaccines: Nanovaccines in the Fight against SARS‐CoV‐2 Virus and beyond SARS‐CoV‐2Semantic proximity Read ↗

mRNA Vaccines: Design Principles, Mechanisms, and Manufacturing—Insights From COVID‐19 as a Model for Combating Infectious DiseasesSemantic proximity Read ↗

Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal modelsSemantic proximity Read ↗

Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious DiseasesSemantic proximity Read ↗

Preclinical evaluation of a candidate naked plasmid DNA vaccine against SARS-CoV-2Semantic proximity Read ↗

Rapid development of a synthetic DNA vaccine for COVID-19Semantic proximity Read ↗

SARS-CoV-2 mRNA Vaccine Development Enabled by Prototype Pathogen PreparednessSemantic proximity Read ↗

Robust and rapid pipeline for the development of mRNA vaccine for the fast-emerging SARS-CoV-2 variantsSemantic proximity Read ↗

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.Semantic proximity Read ↗

Two-Component Nanoparticle Vaccine Displaying Glycosylated Spike S1 Domain Induces Neutralizing Antibody Response against SARS-CoV-2 VariantsSemantic proximity Read ↗

An Update on mRNA-Based Viral VaccinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.